MERIDIAN VENTURE PARTNERS II LP 4/A
4/A · ANI PHARMACEUTICALS INC · Filed Aug 23, 2019
Insider Transaction Report
Form 4/AAmended
MERIDIAN VENTURE PARTNERS II LP
10% Owner
Transactions
- Sale
Common Stock
2019-08-19$68.30/sh−2,067$141,176→ 2,286,795 total - Sale
Common Stock
2019-08-20$68.18/sh−5,512$375,808→ 2,281,283 total
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price, rounded to the nearest cent. The shares were sold pursuant to a Rule 10b5-1 diversification plan entered into by the Reporting Person on June 6, 2019. The shares were sold in multiple transactions at prices ranging from $68.00 to $69.05 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by the Reporting Person at each separate price on each date of sale.
- [F2]The price reported in Column 4 is a weighted average price, rounded to the nearest cent. The shares were sold pursuant to a Rule 10b5-1 diversification plan entered into by the Reporting Person on June 6, 2019. The shares were sold in multiple transactions at prices ranging from $68.00 to $68.80 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold by the Reporting Person at each separate price on each date of sale.
- [F3]Meridian Venture Partners II, Co. (MVP Corp.) is the general partner of Meridian Venture Partners II GP, L.P. (GP), the general partner of Meridian Venture Partners II, L.P. (MVP II). Robert E. Brown, Jr., a director of the issuer, is the President, sole stockholder and sole director of MVP Corp., as well as a limited partner of GP and one of two principals of MVP II.
- [F4]This Form 4 Amendment is being filed for the sole purpose of reporting that sales under the Reporting Person's 10b5-1 diversification plan has completed, and no further sales will take place under the plan.